No drug has been found to have any impact on progressive multiple sclerosis ( MS ). Biotin is a vitamin acting as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids synthesis. Among others, Biotin activates acetylCoA carboxylase, a potentially rate-limiting enzyme in myelin synthesis.
The aim of this uncontrolled, non-blinded proof of concept study was to assess the clinical efficacy and safety of high doses of Biotin in patients suffering from progressive multiple sclerosis.
23 consecutive patients with primary and secondary progressive multiple sclerosis originated from three different French MS reference Centers were treated with high doses of Biotin ( 100–300 mg/day ) from 2 to 36 months ( mean=9.2 months ).
In four patients with prominent visual impairment related to optic nerve injury, visual acuity improved significantly.
Visual evoked potentials in two patients exhibited progressive reappearance of P100 waves, with normalization of latencies in one case.
Proton magnetic resonance spectroscopy ( H-MRS ) in one case showed a progressive normalization of the Choline / Creatine ratio.
One patient with left homonymous hemianopia kept on improving from 2 to 16 months following treatment׳s onset.
Sixteen patients out of 18 ( 89% ) with prominent spinal cord involvement were considered as improved as confirmed by blinded review of videotaped clinical examination in 9 cases.
In all cases improvement was delayed from 2 to 8 months following treatment׳s onset.
In conclusion, these preliminary data suggest that high doses of Biotin might have an impact on disability and progression in progressive multiple sclerosis. ( Xagena )
Sedel F et al, Mult Scler Relat Disord 2015; 4 : 159–169